Coherus Biosciences (NASDAQ:CHRS) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Thursday.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright set a $28.00 target price on shares of Coherus Biosciences and gave the company a “buy” rating in a research note on Monday, November 5th. Cowen reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Coherus Biosciences in a research note on Friday, November 2nd. Zacks Investment Research raised shares of Coherus Biosciences from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Tuesday, October 30th. Maxim Group reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Coherus Biosciences in a research note on Tuesday, September 25th. Finally, ValuEngine cut shares of Coherus Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $27.20.

Coherus Biosciences stock traded up $0.17 during trading hours on Thursday, hitting $12.37. 694,360 shares of the company traded hands, compared to its average volume of 935,337. The stock has a market cap of $785.01 million, a price-to-earnings ratio of -2.76 and a beta of 3.38. The company has a current ratio of 5.31, a quick ratio of 5.31 and a debt-to-equity ratio of 8.29. Coherus Biosciences has a 1-year low of $8.32 and a 1-year high of $20.66.

Coherus Biosciences (NASDAQ:CHRS) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.87) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.79) by ($0.08). Research analysts expect that Coherus Biosciences will post -3.12 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in CHRS. Rhumbline Advisers grew its stake in shares of Coherus Biosciences by 26.9% in the 2nd quarter. Rhumbline Advisers now owns 45,081 shares of the biotechnology company’s stock worth $631,000 after purchasing an additional 9,549 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Coherus Biosciences by 5.3% in the second quarter. Bank of New York Mellon Corp now owns 186,287 shares of the biotechnology company’s stock worth $2,608,000 after acquiring an additional 9,299 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Coherus Biosciences by 21.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 256,214 shares of the biotechnology company’s stock worth $3,587,000 after acquiring an additional 45,144 shares in the last quarter. Swiss National Bank increased its position in shares of Coherus Biosciences by 7.6% in the second quarter. Swiss National Bank now owns 70,500 shares of the biotechnology company’s stock worth $987,000 after acquiring an additional 5,000 shares in the last quarter. Finally, BlackRock Inc. increased its position in shares of Coherus Biosciences by 24.3% in the second quarter. BlackRock Inc. now owns 4,144,082 shares of the biotechnology company’s stock worth $58,018,000 after acquiring an additional 810,358 shares in the last quarter. 93.31% of the stock is currently owned by institutional investors.

About Coherus Biosciences

Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.

Featured Story: What strategies should day traders use to execute a trade?

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.